facebook button Ipsen Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Ipsen Napoli: First Line Onivyde, Oxaliplatin, and 5-FU/Leucovorin Versus Gemcitabine and Nab-Paclitaxel

Sponsor: Ipsen

Protocol D-US-60010-001: An Open-label, randomised, multicentre, phase III study of Irinotecan liposome injection, Oxaliplatin, 5-fluorouracil/Leucovorin versus Nab-paclitaxel plus Gemcitabine in subjects who have not previously received chemotherapy for metastatic Adenocarcinoma of the Pancreas.

For more information please contact the clinical research department: 631-675-5075